Abstract:
One of the most severe diffuse liver diseases is chronic viral hepatitis C (CHC) combined with non-alcoholic fatty
liver disease (NAFLD). After completing the treatment of CHC with drugs of direct antiviral action, there remains a high risk of
further progression of liver fibrosis associated with the presence of comorbid pathology - NAFLD in patients. The above
circumstances initiated us to search for new non-drug technologies to treat this category of patients. Purpose of the work: to study
the effectiveness of use bentonite suspension in rats with a model of NAFLD and to substantiate the practicality of using bentonite
in the complex treatment of CHC patients with concomitant NAFLD. Methods: experimental, anamnestic and clinical, general
clinical, biochemical, determination of the HOMA index, leptin and adiponectin levels, ultrasonographic studies of the digestive
system, bacteriological examination of feces, statistical methods.Results: According to microscopic examination, bentonite
application in animals with the NAFLC model leads to a decrease in liver steatosis, restoration of bile formation and bile secretion,
and protein-synthesizing liver function. In the blood, there was a positive dynamics to the restoration of energy-dependent
transmembrane ion transport according to the activity of Na+/K+ -ATPase and Mg2+/Ca2+ -ATPase (in the liver tissue) and the
balance of the antioxidant system (to restrain malondialdehyde and catalase activity). We examined 40 patients with CHC with
concomitant NAFLD, who completed the course of antiviral therapy (AVT) and were divided into two groups. 1 (control) group (20
people) received a basic treatment complex (diet therapy, which corresponded to the Mediterranean diet, a regimen of dosed
physical exertion, patients of 2 groups (20 people, the main group) additionally received a preparation based on bentonite clay inside
- 10 days (1 dose three times a day) Evaluation of the effectiveness of treatment was carried out one month after the start of
treatment. Conclusion: The treatment carried out in both groups was accompanied by positive dynamics in most of the diseaseʹs
symptoms. But a significant advantage was observed in the second group, where the normalization of cholestatic and dyslipidemic
syndromes was established, that is, the effect on the pathogenetic links of the progression of NAFLD was proved. The results
obtained confirm the practicality of using the drug with bentonite in the complex treatment of CHC patients with concomitant
NAFLD.
